DXCM · NASDAQ · STOCK
DexCom (DXCM) Stock Analysis
$84.09
52W $54.11 – $92.59
63/100
$31.74B
32.5
1.48
Is DXCM Bullish or Bearish?
Bullish.
Innellis AI committee rates Dexcom (DXCM) Buy with a composite score of 63/100
, based on 5 analysts with 60% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +11.95 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -8.05 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 79.4% yoy. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 36.2% shows genuine earnings power backing the valuation — Value
- EPS growing 79.4% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- News sentiment is positive (+0.20 across 21 articles, 14d) — News
Bear Case
- P/E of 31.9 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
63/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 14%
of 192 Healthcare peers
Value Analyst
neutral
54
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 36.2% shows genuine earnings power backing the valuation
− P/E of 31.9 is moderate-to-rich
Growth Analyst
bullish
79
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 79.4% YoY
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 21 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 63.0 to 63.0.
- New bearish signals: 1 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
36.7
Neutral
MACD Histogram
-0.420
Bearish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Mixed
Support
$82.60
Resistance
$88.32
Bollinger %B
0.15
Inside Bands
Price vs Moving Averages
EMA 9
$85.14
Below
EMA 21
$86.01
Below
EMA 50
$84.85
Below
EMA 200
$77.00
Above
Fundamental Analysis
Valuation
43
Growth
95
Profitability
100
Financial Health
88
Cash Flow
70
Valuation
P/E Ratio
32.5×
P/B Ratio
12.31×
PEG Ratio
0.43
Dividend Yield
0.00%
52W High
$92.59
52W Low
$54.11
Quality & Growth
ROE
3045.5%
ROA
1319.1%
Gross Margin
6247.3%
Operating Margin
2292.3%
Revenue Growth YoY
—
Debt / Equity
0.53
AI Fundamental Assessment
P/E ratio of 32.5 (rich relative to a 15-40x range); Price-to-book of 12.3x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 30.5%; Return on assets of 13.2%; Net margin of 20.1%; Gross margin of 62.5%; Current ratio of 1.73 (healthy short-term liquidity); Debt-to-equity of 0.53; Free cash flow per share is positive (3.66); Most recent quarter beat estimates by 12.4%; 5 consecutive earnings beats; EPS growth accelerating (+0.0% -> +25.0% QoQ); Average YoY EPS growth of 45.8%; Analyst estimates rising over recent quarters
Get the Full DXCM Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →